Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)
States sued manufacturer of antitdepressant Paxil, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled for $14 million.
Connecticut v. Mylan Laboratories, Inc. (In re Lorazepam & Clorazepate Antitrust Litigation), MDL No. 1290 (D.D.C. June 15, 2000) 205 F.R.D. 369 (D.D.C. 2002); No. 98 CV 3115 (D.D.C. 2000) – complaint
Plaintiff States alleged that Mylan Laboratories, Inc.(Mylan) and other drug companies entered into illegal agreements to monopolize the market for certain generic anti-anxiety drugs.
Louisiana v. Borden, Inc. No. 95-CA-2655, 684 So.2d 1024 (1996); on remand, 1995 WL 59548 (E.D. La.)
This case was based on a bid-rigging guilty plea by defendant obtained by the U.S. DOJ criminal division in the western district of Louisiana.
Louisiana v. Brunswick Bowling and Billiards Dover, Inc., et al. No. 95-CA-797 665 So.2d 520 (La. App. 5 Cir. 1995)
Defendants conspired to fix prices, enforced by a group boycott and price discrimination
Louisiana v. Classic Softtrim, Inc., No. 95-CA-804, 663 So.2d 835 (La. App. 5 Cir. 1995), 688 So.2d 105 (1997)
Defendant attempted to monopolize the Louisiana market for leather seats in the auto industry.
New York v. Microsoft Corp., 97 F. Supp. 2d 59 (D.D.C. 2000)
U.S. Department of Justice and the Plaintiff States alleged that the Defendant, Microsoft Corporation violated State and Federal law by maintaining a monopoly in the market for Intel-compatible personal computer operating systems and by illegally tying its Windows operating system to its Internet Explorer browser.
U.S. v. First Data Corporation and Concord EFS, Inc., 1:03CV02169 (D.D.C. filed 10/23/03)
The U.S. Department of Justice (DOJ) and Plaintiff States sought to enjoin the merger between First Data Corporation (First Data) and Concord EFS, Inc. (Concord), alleging that the merger would substantially lessen competition in the financial services market.
Texas v. Zeneca, 1997 U.S. Dist. LEXIS 13153 (N.D. Tex. 1997)
States sought an injunction and monetary damages from Zeneca, Inc. (Zeneca), alleging that the company conspired with distributors of its crop protection chemicals to maintain the resale price of the chemicals.
In Re: Insurance Antitrust Litigation, 938 F.2d 919, 1991-1 Trade Cases (CCH) & 69,460
Plaintiff States sought damages and injunctive relief, alleging that Defendant reinsurers, brokers and trade organizations conspired to reduce the availability to public entities of commercial general liability insurance during the mid-1980s.
In re: Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.) (see also Ohio v. Bristol Myers Squibb
Plaintiff States sought damages and injunctive relief, alleging that Bristol-Myers Squibb Co. (BMS) attempted to maintain an unlawful monopoly on buspirone hydrochloride, a medication used to treat generalized anxiety. In settling, BMS agreed to a stipulated injunction and to reimburse consumers and state and local public entities for overcharges. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlement, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.
